4H-1-benzopyran-4-one derivatives, process for their preparation and their use as medicaments.
Abstract
Vorliegende Erfindung betrifft neue 4H-1-Benzopyran-4- on-derivate, Verfahren zu deren Herstellung sowie deren Verwendung als Antiphlogistika, Analgetika, Immunsuppressiva und Antiallergika. Insbesondere betrifft vorliegende Erfindung neue Verbindungen der Formel I, worin R, für Wasserstoff, Alkyl mit 1 bis 6 Kohlenstoffatomen, Aryl-C1-C4-alkyl, substituiertes C1-C8-Alkyl, C3-C8-Cycloalkyl, C3-C6-Cycloalklyl-C1-C4-alkyl, C2-C6-Alkenyl, C2-C6-Alkinyl, Aryl, Carboxyl oder eine Aldehyd- oder COO-C1-C4-Alkylgruppe, R2 für Wasserstoff, Alkyl mit 1 bis 6 Kohlenstoffatomen, Nitro, Amino, Aryl, Carboxyl, Di-C1-C4-alkylamino, oder ein Halogen, R3 für C1-C4-Alkyl, substituiertes C1-C4-Alkyl, Hydroxyl, C1-C4-Alkoxy,Aryl-C1-C4-alkyl, Nitro, Amino, eine C1-C4-Alkyl- oder di-C1-C4-alkylaminogruppe oder Halogen, R4 für Wasserstoff, Hydroxyl, C1-C4-Alkoxy, C1-C4-Alkanoyloxy, C1-C4-Alkoxycarbonyl, Aryloxy, Amino oder eine C1-C4-Alkyl- oder Di-C1-C4-Alkylaminogruppe, n für die ganze Zahl 0, 1 oder 2 und R5 für Wasserstoff, C1-C6-Alkyl, substituiertes C1-C6-Alkyl,Aryl-C1-C4-alkyl, C3-C6-Cycloalkyl, C3-C6-Cycloalkyl-C1-C4-alkyl, C1-C4-Alkanoyl oder Aroyl, wobei die Arylgruppe gegebenenfalls einfach oder mehrfach substituiertes Phenyl ist, stehen, m eine ganze Zahl zwischen 0 und 3 und n eine ganze Zahl zwischen 0 und 2 bedeuten, sowie deren pharmakologisch unbedenkliche Säuradditionssalze.

Term
Term ended
Expired 8 October 2007, 19 years ago.
- Priority
- Filed
- Granted
- Expired
- Today
11 claims: 11 independent, 0 dependent
- 1CLAIMS PATENTANSPRÜCHE 1. Process for the preparation of compounds of the formula I 1. Verfahren zur Herstellung von Verbindungen der Formel I R5 in which mean:R5 worin bedeuten: Rj Wasserstoff, unsubstituiertes oder substituiertes Cj-Cg-Alkyl, Aryl-Cj-alkyl, Cß-Cg-Cycloalkyl, CyCgCycloalkyl-Cj-C4-alkyl, C2-Cg-Alkenyl, CyCg-Alkinyl, Aryl, Carboxyl oder eine Aldehyd- oder - COO-CjC4-Alkyl-Grappe, Rj is hydrogen, unsubstituted or substituted Cj-Cg-alkyl, aryl-Cj-alkyl, Cβ-Cg-cycloalkyl, CyCgCycloalkyl-Cj-C4alkyl, C2-Cg alkenyl, CyCg alkynyl, aryl, carboxyl or an aldehyde or - COO-CjC4Alkyl Grappa, R2 Hydrogen, Cj-Cg-alkyl, nitro, amino, di-Cj-C ^ -alkylamino or di-Cj-C4alkylaminomethyl or a halogen atom, R2 Wasserstoff, Cj-Cg-Alkyl, Nitro, Amino, Di-Cj-C^-alkylamino oder Di-Cj-C4-alkylaminomethyl oder ein Halogenatom, Rss Cj-C4Alkyl, substituted Cj-C4Alkyl, hydroxy, Cj-C4Alkoxy, aryl-Cj-C4alkyl, nitro, halogen, amino, C jC4- or di-Cj-C4alkylamino, Rß Cj-C4-Alkyl, substituiertes Cj-C4-Alkyl, Hydroxy, Cj-C4-Alkoxy, Aryl-Cj-C4-alkyl, Nitro, Halogen, Amino, C j-C4- oder di-Cj-C4-alkylamino, R4 Hydrogen, hydroxy, Cj-C4Alkoxy, Cj-C4Alkanoyloxy, Cj-C4Alkoxycarbonyl, aryloxy, amino, Cj C4Alkylamino or di (C jC4alkyl) amino, R4 Wasserstoff, Hydroxy, Cj-C4-Alkoxy, Cj-C4-Alkanoyloxy, Cj-C4-Alkoxycarbonyl, Aryloxy, Amino, Cj C4-Alkylamino oder di-(C j-C4-alkyl)amino, Rj Wasserstoff, Cj-Cg-Alkyl, substituiertes Cj-Cg-Alkyl, Aryl-Cj-C4-alkyl, CyCg-Cycloalkyl, C3-Cg Cyclalkyl-C j-C4-alkyl, Cj-C4-Alkanoyl oder Aroyl, n eine ganze Zahl zwischen 0 und 2, m eine ganze Zahl zwischen 0 und 3 sowie deren pharmakologisch unbedenklichen Säureadditionssalze und optischen Isomeren, dadurch gekennzeichnet, daß man eine Verbindung der Formel XII Rj is hydrogen, Cj-Cg-alkyl, substituted Cj-Cg-alkyl, aryl-Cj-C4-alkyl, CyCg-cycloalkyl, C3-Cg Cyclalkyl-C jC4alkyl, Cj-C4Alkanoyl or aroyl, n is an integer between 0 and 2, m is an integer between 0 and 3 and their pharmacologically acceptable acid addition salts and optical isomers, characterized in that a compound of the formula XII -22Nr. 389875 -22Nr. 389875 CH (ΧΠ) where R3, R ^, n and m have the meaning given, with an alkali metal or alkali metal hydride and the alkyl ester of an acid of the formula Rj-COOAlkyl, wherein Rj has the meaning given for formula I, converted to a diketone of the formula ΧΠΙ CH (ΧΠ) worin R3, R^, n und m die genannte Bedeutung haben, mit einem Alkalimetall oder Alkalimetallhydrid und dem Alkylester einer Säure der Formel Rj-COOAlkyl, wobei Rj die zur Formel I genannte Bedeutung hat, umsetzt zu einem Diketon der Formel ΧΠΙ R R R R O and the compound obtained by reaction with a Mineraläue cyclized to a compound of formula I, wherein Rj, R3, R5, m and n have the meaning indicated, R4 the hydroxy group and R2 Is hydrogen, and optionally a compound of formula I, wherein R is5 CH3 is reacted after protection of the hydroxyl groups with cyanogen bromide and the resulting compound is reacted acid or alkaline to give a compound of formula I in which R5 is hydrogen, with suitable electrophilic reagents such as halides, acid chlorides, tosylates or Enoncn to compounds of formula I, wherein R5 is unsubstituted or substituted CjCg-alkyl, aryl-Cj-C4alkyl, CyCg-cycloalkyl or C3-Cg cycloalkyl-Cj-C4-alkyl, optionally a compound of formula I, wherein R is2 Is hydrogen, reacting with a secondary amine hydrochloride and paraformaldehyde to give a compound of the formula I, wherein R2 Dialkylaminomethyl, or optionally a compound of formula I, wherein R is2 Is hydrogen, nitrated to a compound of formula I, wherein R2 NO2 optionally, a compound of formula I, wherein R is2 NO2 is hydrogenated to a compound of formula I, wherein R2 represents the amino group, and optionally a compound of formula I, in which R4 is hydroxy, according to known methods to a corresponding compound of formula I, in which R is4 for hydrogen, Cj-C4Alkoxy, Cj-C4Alkanoyloxy, Cj-C4Alkoxycarbonyl, aryloxy, amino, CpC4-Alkylamino or di- (Cj-C4-alkyl) amino reacted. O und die erhaltene Verbindung durch Umsetzen mit einer Mineralsäue zyklisiert zu einer Verbindung der Formel I, worin Rj, R3, R5, m und n die angebene Bedeutung haben, R4 die Hydroxygruppe und R2 Wasserstoff bedeutet, und gegebenenfalls eine Verbindung der Formel I, worin R5 CH3 bedeutet, nach Schutz der Hydroxylgruppen mit Bromcyan umsetzt und die erhaltene Verbindung sauer oder alkalisch umsetzt zu einer Verbindung der Formel I, worin R5 Wasserstoff bedeutet, mit geeigneten elektrophilen Reagenzien wie Halogeniden, Säurechoriden, Tosylaten oder Enoncn zu Verbindungen der Formel I umsetzt, worin R5 unsubstituiertes oder substituiertes CjCg-Alkyl, Aryl-Cj-C4-alkyl, CyCg-Cycloalkyl oder C3-Cg-Cycloalkyl-Cj-C4-alkyl bedeutet, gegebenenfalls eine Verbindung der Formel I, worin R2 Wasserstoff bedeutet, mit einem sekundären Aminhydrochlorid und Paraformaldehyd umsetzt zu einer Verbindung der Formel I, worin R2 Dialkylaminomethyl bedeutet, oder gegebenenfalls eine Verbindung der Formel I, worin R2 Wasserstoff bedeutet, nitriert zu einer Verbindung der Formel I, worin R2 NO2 bedeutet, gegebenenfalls eine Verbindung der Formel I, worin R2 NO2 darstellt, hydriert zu einer Veibindung der Formel I, worin R2 die Aminogruppe darstellt, und gegebenenfalls eine erhaltene Verbindung der Formel I, in der R4 für Hydroxy steht, nach bekannten Methoden zu einer entsprechenden Verbindung der Formel I, in der R4 für Wasserstoff, Cj-C4-Alkoxy, Cj-C4-Alkanoyloxy, Cj-C4Alkoxycarbonyl, Aryloxy, Amino, CpC4-Alkylamino oder Di-(Cj-C4-alkyl)amino steht, umsetzt. -23Nr. 389875 -23Nr. 389875
- 2Verbindungen der Formel I Second Compounds of the formula I Rs in which mean Rs worin bedeuten:Rj Wasserstoff, unsubstituiertes oder substituiertes CpCg-Alkyl, Aryl-Cj-C4-alkyl, C3-Cg-Cycloalkyl, C3Cg-Cycloalkyl-CpC^-alkyl, C2-Cg-Alkenyl, CyCg-Alkinyl, Aryl, Carboxyl oder eine Aldehyd- oder - COOCj-C4-Alkyl-Gruppe, Rj is hydrogen, unsubstituted or substituted CpCg-alkyl, aryl-Cj-C4alkyl, C3-Cg-cycloalkyl, C3C 9 -cycloalkyl-C 1 -C 12 -alkyl, C2-Cg alkenyl, CyCg alkynyl, aryl, carboxyl or an aldehyde or - COOCj-C4Alkyl group, R2 Hydrogen, Cj-Cg-alkyl, nitro, amino, di-Cj-C4-alkylamino or di-Cj-C ^ alkylaminomethyl or a halogen atom, r3 Cj-C ^ alkyl, substituted Cj-C4Alkyl, hydroxy, Cj-C4Alkoxy, aryl-CpC4alkyl, nitro, halogen, amino, C] -C4- or di-Cj-C4alkylamino, R2 Wasserstoff, Cj-Cg-Alkyl, Nitro, Amino, Di-Cj-C4-alkylamino oder Di-Cj-C^alkylaminomethyl oder ein Halogenatom, r3 Cj-C^-Alkyl, substituiertes Cj-C4-Alkyl, Hydroxy, Cj-C4-Alkoxy, Aryl-CpC4-alkyl, Nitro, Halogen, Amino, C]-C4- oder di-Cj-C4-alkylamino, R4 Hydrogen, hydroxy, Cj-C4Alkoxy, Cj-C4Alkanoyloxy, Cj-C4Alkoxycarbonyl, aryloxy, amino, Cp C4Alkylamino di- (Cj-C4alkyl) amino, R4 Wasserstoff, Hydroxy, Cj-C4-Alkoxy, Cj-C4-Alkanoyloxy, Cj-C4-Alkoxycarbonyl, Aryloxy, Amino, Cp C4-Alkylamino der di-(Cj-C4-alkyl)amino, R5 Wasserstoff, CpCg-Alkyl, substituiertes CpCg-Alkyl, Aryl-Cj-C^alkyl, C3-Cg-Cycloalkyl, C3-C6Cycloalkyl-C]-C4-alkyl, CpC4- Alkanoy1 oder Aroyl, n eine ganze Zahl zwischen 0 und 2, m eine ganze Zahl zwischen 0 und 3, mit Ausnahme der Verbindung 5,7-Dihydroxy-2-methyl-8-[4'-(3'-hydroxy-r-methyl)-piperidinyl]-4H-lbenzopyian-4-on sowie deren pharmakologisch unbedenklichen Säureadditionssalze und optischen Isomeren. R5 is hydrogen, CpCg-alkyl, substituted CpCg-alkyl, aryl-Cj-C ^ alkyl, C3-Cg-cycloalkyl, C3-C6Cycloalkyl-C] -C4alkyl, CpC4Alkanoy1 or aroyl, n is an integer between 0 and 2, m is an integer between 0 and 3, with the exception of the compound 5,7-dihydroxy-2-methyl-8- [4 '- (3'-hydroxy-r -methyl) -piperidinyl] -4H-benzopylyan-4-one and their pharmacologically acceptable acid addition salts and optical isomers.
- 3Verbindungen gemäß Anspruch 2, worin Rj, R2 und R5 die genannte Bedeutung haben, R3 und R4 die Hydroxylgruppe, m die Zahl 2 und n die Zahl 1 bedeuten. Third Compounds according to claim 2, wherein Rj, R2 and R5 have the meaning given, R3 and R4 the hydroxyl group, m is the number 2 and n is the number 1.
- 4Verbindungen gemäß Anspruch 2, worin R] Wasserstoff oder Cj-C3-Alkyl, R2 Wasserstoff oder Cj-C3Alkyl, R3 und R4 jeweils die Hydroxygruppe, Rj CpC3-Alkyl oder CyCg-Cycloalkyl, m die Zahl 2 und n die Zahl 1 bedeuten. 4th Compounds according to claim 2, wherein R] is hydrogen or Cj-C3Alkyl, R2 Hydrogen or Cj-C3Alkyl, R3 and R4 each the hydroxy group, Rj CpC3Alkyl or CyCg-cycloalkyl, m is the number 2 and n is the number 1.
- 5cis-(±)-2-(2-Chloiphenyl)-5,7-dihydroxy-8-[4'-(3,-hydroxy-r-methyl)piperidinyl]-4H-l-benzopyran-4-on sowie dessen pharmakologisch unbedenklichen Säureadditionssalze. 5th cis- (±) -2- (2-Chloiphenyl) -5,7-dihydroxy-8- [4 '- (3,-hydroxy-r-methyl) piperidinyl] -4H-1-benzopyran-4-one and its pharmacologically acceptable acid addition salts.
- 6cis-(-)-2-(2-Chlorphenyl)-5,7-dihydroxy-8-[4'-(3'-hydroxy-l-methyl)piperidinyl]-4H-l-benzopyran-4-on sowie dessen pharmakologisch unbedenklichen Säureadditionssalze. 6th cis - (-) - 2- (2-chlorophenyl) -5,7-dihydroxy-8- [4 '- (3'-hydroxy-1-methyl) piperidinyl] -4H-1-benzopyran-4-one and its pharmacologically acceptable acid addition salts. -24Nr. 389875 -24Nr. 389875
- 7cis-(-)-2-Phenyl-5,7-dihydroxy-8-[4'-(3'-hydroxy-r-methyl)piperidinyl]-4H-l-benzopyran-4-on sowie dessen pharmakologisch unbedenklichen Säureadditionssalze. 7th cis - (-) - 2-phenyl-5,7-dihydroxy-8- [4 '- (3'-hydroxy-r-methyl) piperidinyl] -4H-1-benzopyran-4-one and its pharmacologically acceptable acid addition salts.
- 8cis-(±)-2-Phenyl-5,7-dihydroxy-8-[4'-(3'-hydroxy-r-methyl)piperidinyl]-4H-l-benzopyran4-on sowie dessen pharmakologisch unbedenklichen Säureadditionssalze. 8th. cis- (±) -2-phenyl-5,7-dihydroxy-8- [4 '- (3'-hydroxy-r-methyl) piperidinyl] -4H-1-benzopyran4-one and its pharmacologically acceptable acid addition salts.
- 910 9. cis- (±) -2- (p -Huorphenyl) -5,7-dihydroxy-8- [4 '- (3'-hydroxy-1-methyl) -piperidinyl] -4H-1-benzopyran-4 on and its pharmacologically acceptable acid addition salts. 10 9. cis-(±)-2-(p-Huorphenyl)-5,7-dihydroxy-8-[4’-(3'-hydroxy-l'-methyl)piperidinyl]-4H-l-benzopyran-4-on sowie dessen pharmakologisch unbedenklichen Säureadditionssalze. 10. cis-(±)-2-(2-pyridyl)-8-[4'-(3'-hydroxy-l'-methyl)-piperidinyl]-4H-benzopyran-4-on sowie dessen 15 pharmakologisch unbedenklichen Säureadditionssalze. 10th cis- (±) -2- (2-pyridyl) -8- [4 '- (3'-hydroxy-1-methyl) -piperidinyl] -4H-benzopyran-4-one and its 15 pharmacologically acceptable acid addition salts.
- 1011. Arzneimittel, gekennzeichnet durch einen Gehalt an einer Verbindung der Formel I gemäß Anspruch 2 oder einem pharmakologisch unbedenklichen Säureadditionssalz. 11th Medicament, characterized by a content of a compound of the formula I according to claim 2 or a pharmacologically acceptable acid addition salt.
- 1112. Verwendung einer Verbindung gemäß Anspruch 2 zur Herstellung eines Arzneimittels mit entzündungshemmender und/oder immunmodulierender Wirkung. 12th Use of a compound according to claim 2 for the preparation of a medicament having an anti-inflammatory and / or immunomodulating action.
Independent claims11
361 paragraphs in 1 section, as filed
(54) PROCESS FOR THE PREPARATION OF 4H-1-BENZO-PYRANO-4-O-N DERIVATIVES, NEW 4H-1-BENZO-PYRANE-4-O-N DERIVATIVES AND THEIR USE AS MEDICAMENTS (57) A process for the preparation of 4H-1-one is described. Benzopyran-4-one-derviaten and their pharmacologically acceptable acid addition salts and optical isomers. Furthermore, new 4H-1-benzopyran4-one derivatives, their pharmacologically acceptable acid addition salts and optical isomers and the use of these new compounds as anti-inflammatory drugs,
Analgesics, immunosuppressants and antiallergic agents.
CQ
AT 389 875 iroora bite
No. 389875
The present invention relates to a process for the preparation of 4H-l-Bezopyran-4-one derivatives and their pharmacologically acceptable acid addition salts and optical isomers. The invention further relates to novel 4H-l-Bezopyran-4-one derivatives, their pharmacologically acceptable acid addition salts and optical isomers and the use of these new compounds as anti-inflammatory drugs, analgesics, immunosuppressants and antiallergic agents.
The compounds which can be prepared according to the invention are those of the formula I.
<img file="AT389875B_D0001.tif" />
wherein Rj is hydrogen, alkyl of 1 to 6 carbon atoms, aryl-CpC ^ -alkyl, substituted Cj-Cg-alkyl, CyCg-cycloalkyl, Cβ-Cg-cycloalkyl-Cj-C<sub>4</sub>alkyl, C<sub>2</sub>-Cg-alkenyl, Cß-Cg-alkynyl, aryl, carboxyl or an aldehyde or COO-Cj-C ^ alkyl group, R<sub>2</sub> is hydrogen, alkyl of 1 to 6 carbon atoms, nitro, amino, di-C 1 -C 4 -alkylamino, di-C 1 -C 4 -alkylaminomethyl or a halogen, R 3 is C 1 -C 4<sub>4</sub>Alkyl, substituted Cj-C<sub>4</sub>-Alkyl, hydroxyl, Cj-C ^ alkoxy, aryl-Cj-C ^ alkyl, nitro, amino, a Cj-C<sub>4</sub>-Alky or di-C<sub>1</sub>-C<sub>4</sub>alkylamino group or halogen, R<sub>4</sub> for hydrogen, hydroxyl, C] -C<sub>4</sub>Alkoxy, Cj-C<sub>4</sub>Alkanoyloxy, Cj-C<sub>4</sub>Alkoxycarbonyl, aryloxy, amino or a Cj-C<sub>4</sub>Alkyl or di-Cj-C<sub>4</sub>Alkylamino group, n is the integer 0,1 or 2 and Rg is hydrogen, Cj-Cg-alkyl, substituted Cj-CgAlkyl, aryl-Cj-C<sub>4</sub>alkyl, Cβ-Cg-cycloalkyl, Cβ-Cg-cycloalkyl-Cj-C ^ -alkyl, Cj-C<sub>4</sub>Alkanoyl or aroyl, wherein the aiyl group is optionally mono- or polysubstituted phenyl, m, an integer between 0 and 3 and n is an integer between 0 and 2, and their pharmacologically acceptable acid addition salts and optical isomers.
The process according to the invention for the preparation of these compounds is characterized in that a compound of the formula ΧΠ
<img file="AT389875B_D0002.tif" />
wherein Rβ, Rg, n and m have the meaning given, with an alkali metal or alkali metal hydride and the
-2Nr. 389875
Alkyl esters of an acid of the formula RpCOOAIkyl, wherein Rj has the meaning given for formula I, converted to a diketone of the formula ΧΠΙ
<img file="AT389875B_D0003.tif" />
and the resulting compound cyclized by reaction with a mineral acid to give a compound of formula I wherein Rp Rβ, R ^, m and n are as defined, R<sub>4</sub> the hydroxy group and R<sub>2</sub> Is hydrogen, and optionally a compound of formula I in which R denotes CH.sub.3, after protection of the hydroxyl groups with cyanogen bromide, converts to a compound of formula I wherein R 5 is hydrogen, optionally a compound of formula I in which Rg is hydrogen, with appropriate electrophilic
Reactants such as halides, acid chlorides, tosylates or enones to compounds of formula I, wherein R ^ is unsubstituted or substituted Cj-Cg-alkyl, aryl-Cj-C ^ -alkyl, Cβ-Cg-cycloalkyl or CyCgCycloalkyl-Cj-C<sub>4</sub>-alkyl, optionally a compound of formula I, wherein R is<sub>2</sub> Is hydrogen, reacting with a secondary amine hydrochloride and paraformaldehyde to give a compound of the formula I, wherein R<sub>2</sub> Dialkylaminomethyl, or optionally a compound of formula I, wherein R is<sub>2</sub> Is hydrogen, nitrated to a compound of formula I, wherein R<sub>2</sub> NO<sub>2</sub> optionally, a compound of formula I, wherein R is<sub>2</sub> NO<sub>2</sub> is hydrogenated to a compound of formula I, wherein R<sub>2</sub> represents the amino group, and optionally a compound of formula I, in which R<sub>4</sub> is hydroxy, according to known methods to a corresponding compound of formula I, in which R is<sub>4</sub> for hydrogen, Cj-C<sub>4</sub>Alkoxy, Cj-C<sub>4</sub>Alkanoyloxy, Cj-C<sub>4</sub>Alkoxycarbonyl, aryloxy, amino, Cj-C<sub>4</sub>-Alkylamino or di- (Cj-C<sub>4</sub>-alkyl) amino reacted.
The novel 4H-1-benzopyran-4-one derivatives according to the invention also have the abovementioned general formula I in which R 1 to R 5, n and m have the meanings given above, but the compound is 5,7-dihydroxy-2-methyl -8- [4 '- (3'-hydroxy-r-methyl) -piperidinyl] -4H-1-benzopyran-4-one, or they are pharmacologically acceptable acid addition salts or isomers thereof.
The compounds which can be prepared according to the invention and the novel compounds according to the invention have two asymmetric centers, one at the point of attachment of the nitrogen heterocycle with the benzopyran moiety (C-4 ') and the other at R<sub>4</sub> substituted carbon atom (C-3 '), so that two pairs of optical isomers are possible. It is understood that all possible stereoisomers and their mixtures are included in the definition of the compounds of the invention. In particular, both the racemic forms and the isolated optical isomers possessing the indicated activity are included. The two racemates can be separated by physical methods such as fractional crystallization. The individual optical isomers are obtainable from the racemates by standard methods such as salt formation with an optically active acid and subsequent crystallization.
In EP-A2-0 137 193, the compound 5,7-dihydroxy-2-methyl-8- [4 '- (3'-hydroxy-r-methyl) piperidinyl] -4H-1-benzopyrano-4 is already known. in the trans (+) form, their isolation from the plant Dysoxylum binectariferum and their use as immunomodulating agents. This compound is therefore present from the new 4H-1-benzopyran-4-one derivatives<sup>-</sup> excepted.
As alkyl groups for Rj-Rj are, for example, straight-chain or branched radicals having up to 6 and preferably up to 5 carbon atoms, for. For example, methyl, ethyl, propyl, isopropyl, t-butyl, pentyl or
Isopentyl.
Suitable substituted alkyl groups for Rj-Rj are, for example, haloalkyl, such as trifluoromethyl,
-3Nr. 389875
Hydroxyalkyl such as hydroxyethyl or carboxyalkyl such as carboxyethyl.
Suitable examples of a cycloalkyl group Rj and Rg having 3 to 6 carbon atoms are cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. Cycloalkylalkyl is, for example, cyclopropylmethyl.
An aralkyl group R | and Rg is, for example, a phenylalkyl group in which the phenyl group is optionally substituted by substituents such as halogen, Cj-C ^ alkyl, C<sub>1</sub>-C<sub>4</sub>Alkoxy, nitro or a trifluoromethyl group is monosubstituted or polysubstituted.
An aryl group Rj and Rg is, for example, a phenyl group optionally substituted by substituents such as halogen, Cj-C<sub>4</sub>Alkyl, C jC<sub>4</sub>Alkoxy, nitro or trifluoromethyl is monosubstituted or polysubstituted
As a suitable example of alkylamino Rj and R<sub>5</sub> comes (CH<sub>2</sub>)<sub>n</sub>In which n is 1-3 and Rg and Ry are alkyl having the same meaning as described above for alkyl Rj-Rg: in addition, Rg and Ry, together with the nitrogen atom to which they are attached, may be a heterocycle having one or more substituents represent several heteroatoms. Suitable examples of heterocycles formed by Rg and Ry together with the nitrogen to which they are attached are piperidine, pyrrolidine, morpholine, piperazine or imidazole, optionally substituted at one or more positions by C jC<sub>4</sub>Alkyl, Cj-C<sub>4</sub>Alkoxy, aryl, or a hydroxyl or amino group.
Suitable examples of salts of the compounds according to the invention with inorganic or organic acids are the hydrochloride, hydrobromide, sulfate, phosphate, acetate, oxalate, tartrate, citrate, maleate or fumarate.
Preferred compounds correspond to the formula Ia,
<img file="AT389875B_D0004.tif" />
wherein Rj, R<sub>2</sub> andRg have the same meanings as described above and in particular mean:
Rj is hydrogen or Cj-Cg-alkyl R<sub>2</sub> Is hydrogen or Cj-Cβ-alkyl Rg Cj-CyAlkyl or CyCg-cycloalkyl, where the combination of the meanings R j = CH<sub>3</sub>, R<sub>2</sub> = H and Rg = CHg is excluded.
Particularly preferred compounds according to the invention are:
cis - (-) - 5,7-Dihydroxy-2-methyl-8- [4 '- (r -cyclopropylmethyl-3'-hydroxy) -piperidinyl] 4H-l'benzopyran4-one, cis- (±) 5,7-dihydroxy-2-ethyl-8- [4 '- (3'-hydroxy-r-methyl) -piperidinyl] -4H-1-benzopyran-4-one and cis - (+) - 5,7- dihydroxy-2-n-propyl-8- [4 '- (3'-hydroxy-r-methyl) piperidinyl] -4-l-benzopyran-4-one.
£ 12 - (+) - 5,7-dihydroxy-2-n-propyl-8- [4 '- (3'-hydroxy-r-methyl) piperidinyl-4H-l-benzopyran-4-one. cis - (-) - 5,7-dihydroxy-2-n-propyl-8-i4 '- (3'-hydroxy-r-methylpiperidinyl-14H-1-benzopyran-4-one, cis (i) -2-n Butyl-5,7-dihydroxy-8-r4 '- (3'-hydroxy-1-methyl) piperidinyn-4H-1-benzopyran-4-one, cis-fi) -5.7-dihydroxy-2-phenvl-8- r4'-f3<sup>,</sup>hydroxy-r-methyl) piperidinyll-4H-l-benzopyran-4-one.
£ 15 - (-) - 5,7-Dihydroxy-2-phenyl-8- [4 '- (3'-hydroxy-r-methyl) -piperidinyl] -4H-1-benzopyran-4-one, εS- ( ±) -2- (2-CMorophenyl) -5,7-dihydroxy-8- [4 '- (3<sup>,</sup>hydroxy-r-rnethyl) piperidinyl] -4H-benzopyran-4-one.
cis - (- ~> -2- (2-chlorophenyl) -5,7-dihydroxy-8-i4 '- (3'-hydroxy-r-methyl) piperidinyll-4H-l-benzopyran-4-one.
£ iS- (±) -2- (4-aminophenyl) -5,7-dihydroxy-8- [4 '- (3'-hydroxy-r-methyl) piperidinyl] -4H-l-benzopyian-4-one.
£ is- (±) -2- (4-Bromophenyl) -5,7-dihydroxy-8- [4<sup>,</sup>- (3'-hydroxy-r-methyl) piperidmyl] -4H-l-benzopyran-4-one.
-4Nr. 38,98575 is- (±) -2- (4-c.Morophenyl) -5,7-dihydroxy-8- [4 '- (3'-hydroxy-r-methyl) piperidinyl] -4H-1-benzopyran-4-one ,
£ is- (±) -2- (2,4-dichlorophenyl) -5,7-dihydroxy-8- [4<sup>,</sup>- (3'-hydroxy-l<sup>,</sup>methyl) piperidinyl] -4H-l-benzopyran-4-one.
2iS- (±) -5,7-dihydroxy-2- (4-fluOTophenyl) -8- [4 '- (3'-hydroxy-l-methyl) piperidinyl] -4H-l-benzopyran-4-one.
£ is- (±) -5,7-dihydroxy-2- (2-fluorophenyl) -8- [4 '- (3'-hydroxy-r-methyl) piperidinyl] -4H-l-benzopyran-4-one.
£ is- (±) -5,7-dihydroxy-2- (4-methylphenyl) -8- [4<sup>,</sup>- (3'-hydroxy-r-methyl) piperidinyl] -4H-l-benzopyran-4-one.
£ iS- (±) -5,7-dihydroxy-2- (2-pyridyl) -8- [4 '- (3'-hydroxy-r-methyl) piperidinyl] -4H-l-benzopyran-4-on.
£ iS- (±) -5,7-dihydroxy-2- (4-pyridyl) -8- [4 '- (3'-hydroxy-r-methyl) piperidinyl] -4H-l-benzopyran-4-one.
New 4H-1-benzopyran-4-one derivatives according to the invention are listed in Tables 1 to 5 below, reference being made to the following formulas:
Formula lb
<img file="AT389875B_D0005.tif" />
Formula Ic
<img file="AT389875B_D0006.tif" />
-5Nr. 389875
Formula Id
Rs i
<img file="AT389875B_D0007.tif" />
-6Nr. 389875
Table 1
Compounds of the formula Ib
<td><sup>R</sup>5</td><td>Melting point of the base</td><td>X</td><td>Melting point of the salt</td>
<td>H</td><td> >300°</td><td></td><td></td>
<td>CN</td><td> 212-14°</td><td></td><td> -</td>
<td>c<sub>2</sub>H<sub>5</sub></td><td> -</td><td>HC1.H<sub>2</sub>O</td><td> >300°</td>
<td>ch<sub>2</sub>ch<sub>2</sub>cn</td><td> 200-2°</td><td> -</td><td> -</td>
<td colspan="4">0. II</td>
<td>P-C1-C<sub>6</sub>H<sub>4</sub>-C-</td><td> -</td><td>H<sub>2</sub>O</td><td> 178-80°</td>
<td>c<sub>6</sub>H<sub>4</sub>ch<sub>2</sub>-</td><td> 214-16°</td><td> -</td><td> -</td>
<td>(CH<sub>2</sub>)<sub>2</sub>CH (CH<sub>3</sub>)<sub>2</sub></td><td> -</td><td>HC1.3H<sub>2</sub>O</td><td> 265-68°</td>
<td>ch<sub>2</sub>cook</td><td> -</td><td>4.h<sub>2</sub>O</td><td>250-53 ° (Z)</td>
<td colspan="4">0 II</td>
<td>c-ch<sub>2</sub>cooch<sub>3</sub></td><td> -</td><td>H<sub>2</sub>°</td><td> 185-88°</td>
<td>ch<sub>2</sub>ch = ch<sub>2</sub></td><td> -</td><td>HCl</td><td> 235-38°</td>
<td>pfc<sub>6</sub>H<sub>4</sub>ch<sub>2</sub></td><td> -</td><td>HCl</td><td> 260-63°</td>
<td colspan="4">0 II</td>
<td>pFC<sub>6</sub>H<sub>4</sub>-NH-C</td><td> 236-39°</td><td> -</td><td> -</td>
<td>p-CN-C<sub>6</sub>H<sub>4</sub>ch<sub>2</sub></td><td> -</td><td>HC1.1 1/2 H<sub>2</sub>O</td><td> 224-26°</td>
<td>ch<sub>2</sub>ch<sub>2</sub>Oh</td><td> -</td><td>ch<sub>3</sub>Oh</td><td> 202-5°</td>
<td>m-CF ^ ^ H ^ -C CEL ·</td><td> -</td><td>HC1.1 1/2 H<sub>2</sub>O</td><td> 173-75°</td>
<td colspan="4">0 II</td>
<td>c<sub>6</sub>H<sub>5</sub>c-ch<sub>2</sub></td><td> -</td><td>HC1.1 / 2 H<sub>2</sub>O</td><td> >200°</td>
<td><sup>C</sup>6<sup>H</sup>11</td><td> -</td><td>HC1.1 1/2 H<sub>2</sub>O</td><td> >200°</td>
<td>CH (CH<sub>3</sub>)<sub>2</sub></td><td> >210°</td><td>hci.h<sub>2</sub>O</td><td> -</td>
<td><sup>ch</sup>2—<1</td><td> -</td><td>hci.h<sub>2</sub>O</td><td> >210°</td>
-7Nr. 389875
Table 2
Compounds of the formula Ic
<td>r<sub>4</sub></td><td><sup>R</sup>5</td><td> 00 &</td><td><sup>R</sup>9</td><td>X {</td><td>melting point</td>
<td>OCOCH<sub>3</sub></td><td>CN</td><td>coch<sub>3</sub></td><td>coch<sub>3</sub></td><td></td><td> 207-9°</td>
<td>och<sub>9</sub>ch = ch<sub>9</sub></td><td>ch<sub>9</sub>ch = ch<sub>9</sub></td><td>Η</td><td>H</td><td>HCl</td><td> 235-38°</td>
<td>OHfcis)</td><td>ch<sub>2</sub>co<sub>2</sub>c<sub>2</sub>H<sub>5</sub></td><td>Η</td><td colspan="2">CH<sub>9</sub>CO<sub>9</sub>C<sub>9</sub>H<sub>S</sub> H<sub>9</sub>O</td><td> 185-88°</td>
<td>OH (trans)</td><td>ch<sub>3</sub></td><td>Η</td><td>H</td><td>HCl. 1/2 H<sub>2</sub>0</td><td> >290°</td>
<td>o-ch<sub>2</sub>-c<sub>6</sub>H<sub>5</sub></td><td>ch<sub>3</sub></td><td>Η</td><td>H</td><td> -</td><td> 238-40°</td>
<td>0 II</td><td></td><td></td><td></td><td></td><td></td>
<td>oc-ch<sub>3</sub></td><td>ch<sub>3</sub></td><td>coch<sub>3</sub></td><td>H</td><td>HC1.2H<sub>2</sub>O</td><td> 192-94°</td>
<td>0 II</td><td></td><td></td><td></td><td></td><td></td>
<td>oc-ch<sub>3</sub></td><td>ch<sub>3</sub></td><td>Η</td><td>H</td><td>HCl</td><td> 195-99°</td>
<td>Please refer</td><td></td><td></td><td></td><td></td><td></td>
<td>Formula VI</td><td>ch<sub>3</sub></td><td>Η</td><td>H</td><td>H<sub>2</sub>°</td><td> 226-28°</td>
<td>OH</td><td>ch<sub>3</sub></td><td>SO<sub>9</sub>NH<sub>9</sub></td><td>H</td><td>H<sub>9</sub>SO<sub>4</sub>.2 1/2 H<sub>9</sub>0</td><td> 277-80°</td>
<td>OH ftrans)</td><td>ch<sub>3</sub></td><td>ch<sub>3</sub></td><td>ch<sub>3</sub></td><td> -</td><td> >250°</td>
<td>OH (cis)</td><td>ch<sub>3</sub></td><td>ch<sub>3</sub></td><td>ch<sub>3</sub></td><td> -</td><td> 236-39°</td>
<td>Oh fcis)</td><td><sup>C</sup>2<sup>H</sup>5</td><td>ch<sub>3</sub></td><td>ch<sub>3</sub></td><td>HC1.1 / 2 H<sub>2</sub>0</td><td> 240-42°</td>
<td>OH (cis)</td><td>ch<sub>3</sub></td><td>Η</td><td>ch<sub>3</sub></td><td>HCl</td><td> 230-32°</td>
<img file="AT389875B_D0008.tif" />
-8Nr. 389875. Table 3
Compounds of the formula Id
<td><sup>R</sup>1</td><td><sup>R</sup>2</td><td><sup>R</sup>3</td><td><sup>R</sup>5</td><td>X</td><td>melting point</td>
<td>ch<sub>3</sub></td><td>H</td><td>br</td><td>ch<sub>3</sub></td><td>HCl</td><td> >300°</td>
<td>ch<sub>3</sub></td><td>CH<sub>2</sub>N (CH<sub>3</sub>)<sub>2</sub></td><td>br</td><td>ch<sub>3</sub></td><td>2HC1.2H<sub>2</sub>O</td><td> >300°</td>
<td>ch<sub>3</sub></td><td>see formula VII</td><td>H</td><td>ch<sub>3</sub></td><td>2HC1.H<sub>2</sub>O</td><td> 194-96°</td>
<td>ch<sub>3</sub></td><td>no<sub>2</sub></td><td>H</td><td>ch<sub>3</sub></td><td>HC1.1 1/2 H<sub>2</sub>O</td><td>272-75 ° (Z)</td>
<td>ch<sub>3</sub></td><td>br</td><td>H</td><td>ch<sub>3</sub></td><td> -</td><td> 275-76°</td>
<td>ch<sub>3</sub></td><td>nh<sub>2</sub></td><td>H</td><td>ch<sub>3</sub></td><td>hci.h<sub>2</sub>O</td><td> 197-200°</td>
<td>H</td><td>H</td><td>H</td><td>ch<sub>3</sub></td><td> -</td><td>298 ° (Z)</td>
<td>c<sub>2</sub>H<sub>5</sub></td><td>H</td><td>H</td><td>ch<sub>3</sub></td><td>HC1.1 1/2 H<sub>2</sub>O</td><td> 230-33°</td>
<td><sup>n</sup>‘<sup>c</sup>3<sup>H</sup>7</td><td>H</td><td>H</td><td>ch<sub>3</sub></td><td>hci.h<sub>2</sub>O</td><td> 190-92°</td>
Formula VH r ~ \
-HjC-N H
<img file="AT389875B_D0009.tif" />
-9Nr. 389875
Table 4
Compounds of the formula le
<td><sup>R</sup>1</td><td><sup>R</sup>2</td><td><sup>r</sup>4</td><td><sup>R</sup>8</td><td><sup>R</sup>9</td><td>X</td><td>fp ·</td><td>OPL rotation</td>
<td>H</td><td>H</td><td>OH</td><td>H</td><td>H</td><td></td><td>298 ° (d)</td><td> (±)</td>
<td>H</td><td>H</td><td>OH</td><td>ch<sub>3</sub></td><td>ch<sub>3</sub></td><td>HCl, 1.5HoO</td><td> 173-175</td><td> (±)</td>
<td>ch<sub>3</sub></td><td>H</td><td>OH</td><td>H</td><td>H</td><td>HCl</td><td> 237-240</td><td> (±)</td>
<td>ch<sub>3</sub></td><td>H</td><td>OH</td><td>H</td><td>H</td><td>HCl</td><td> 243-43</td><td> (+)</td>
<td>ch<sub>3</sub></td><td>H</td><td>OH</td><td>H</td><td>H</td><td>HCl</td><td> 241-42</td><td> (-)</td>
<td>ch<sub>3</sub></td><td>H</td><td>OH</td><td>H</td><td>ch<sub>3</sub></td><td>HCl</td><td> 230-232</td><td> (±)</td>
<td>ch<sub>3</sub></td><td>H</td><td>OH</td><td>ch<sub>3</sub></td><td>ch<sub>3</sub></td><td>2HC1.2H<sub>2</sub>O</td><td> 236-239</td><td> (±)</td>
<td>ch<sub>3</sub></td><td>H</td><td>H</td><td>H</td><td>H</td><td>H<sub>2</sub>O</td><td> 232-233</td><td> (±)</td>
<td><sup>C</sup>2<sup>H</sup>5</td><td>H</td><td>OH</td><td>H</td><td>H</td><td>HCl, 1.5H<sub>2</sub>0</td><td> 230-233</td><td> (±)</td>
<td><sup>c</sup>2<sup>H</sup>5</td><td>H</td><td>OH</td><td>ch<sub>3</sub></td><td>ch<sub>3</sub></td><td>HCl, 1.5H<sub>2</sub>0</td><td> 240-242</td><td> (±)</td>
<td>nC<sub>3</sub>H<sub>7</sub></td><td>ch<sub>3</sub></td><td>OH</td><td>H</td><td>H</td><td> -</td><td> 191-192</td><td> (±)</td>
<td>nC<sub>3</sub>H<sub>7</sub></td><td>H</td><td>OH</td><td>H</td><td>H</td><td>HCl</td><td> 190-192</td><td> (±)</td>
<td>nC<sub>3</sub>H<sub>7</sub></td><td>H</td><td>OH</td><td>H</td><td>H</td><td>HCl, 0.5H<sub>2</sub>O</td><td> 197-200</td><td> (+)</td>
<td>nC<sub>3</sub>H<sub>7</sub></td><td>H</td><td>OH</td><td>H</td><td>H</td><td>HCl, 0.5H<sub>2</sub>O</td><td> 198-201</td><td> (-)</td>
<td>nC<sub>4</sub>H<sub>9</sub></td><td>H</td><td>OH</td><td>H</td><td>H</td><td>HCl, H<sub>2</sub>O</td><td> 157-159</td><td> (±)</td>
<td>ch<sub>3</sub></td><td>ch<sub>3</sub></td><td>OH</td><td>H</td><td>H</td><td>H<sub>2</sub>O</td><td> 232-233</td><td> (+)</td>
-10Nr. 389875
Table 5
Compounds of the formula If
<td><sup>R</sup>10</td><td> *8</td><td>r<sub>9</sub></td><td>X</td><td>Mp.</td><td>Opt. Rotation</td>
<td>H</td><td>H</td><td>H</td><td>HCl, 2H<sub>2</sub>O</td><td> 273-275°</td><td> (±)</td>
<td>4-NO<sub>2</sub></td><td>H</td><td>H</td><td>HCl, 3H<sub>2</sub>O</td><td>249 ° (d)</td><td> (±)</td>
<td>4-NO<sub>2</sub></td><td>ch<sub>3</sub></td><td>ch<sub>3</sub></td><td>HCl, 2H<sub>2</sub>O</td><td>257-260 ° (d)</td><td> (±)</td>
<td>2-C1</td><td>H</td><td>H</td><td>HCl, H<sub>2</sub>O</td><td> 198-200°</td><td> (±)</td>
<td>2-C1</td><td>ch<sub>3</sub></td><td>ch<sub>3</sub></td><td>1.5HC1, H<sub>2</sub>O</td><td> 190-191°</td><td> (+)</td>
<td>4-NH<sub>2</sub></td><td>H</td><td>H</td><td>2HC1,2H<sub>2</sub>O</td><td> 240-242</td><td> (+)</td>
<td>3,5-di-</td><td></td><td></td><td></td><td></td><td></td>
<td>methoxy</td><td>ch<sub>3</sub></td><td>ch<sub>3</sub></td><td>2HC1,2H<sub>2</sub>O</td><td> 180-182°</td><td> (±)</td>
<td>4-Br</td><td>H</td><td>H</td><td>HCl, 2H<sub>2</sub>O</td><td> 215°</td><td> (±)</td>
<td>4-C1</td><td>H</td><td>H</td><td>HCl, 1.5H<sub>2</sub>O</td><td> 225°</td><td> (±)</td>
<td colspan="2">2,4-dichloro H</td><td>H</td><td>HCl, 2.5H<sub>2</sub>O</td><td> 165-166</td><td> (±)</td>
<td>4-F</td><td>H</td><td>H</td><td>HCl, H<sub>2</sub>O</td><td> 285-287°</td><td> (±)</td>
<td>2-F</td><td>H</td><td>H</td><td>HCl, 2H<sub>2</sub>O</td><td> 263-265</td><td> (±)</td>
<td>4-methyl</td><td>H</td><td>H</td><td>HCl, 1.5H<sub>2</sub>O</td><td> 247-49</td><td> (±)</td>
<td>3,5-di-</td><td></td><td></td><td></td><td></td><td></td>
<td>hydroxy</td><td>H</td><td>H</td><td>HCl, 3H<sub>2</sub>O</td><td> 300-302</td><td> (±)</td>
<td>3-C1</td><td>H</td><td>H</td><td>HCl, 2H<sub>2</sub>O</td><td> 288-290</td><td> (±)</td>
<td>3-methyl</td><td>H</td><td>H</td><td>HCl, 2H<sub>2</sub>O</td><td> 268°</td><td> (±)</td>
<td>2-methyl</td><td>H</td><td>H</td><td> -</td><td> 204-205</td><td> (±)</td>
<td>2-C1</td><td>H</td><td>H</td><td>HCl, 2H<sub>2</sub>O</td><td> 190-192</td><td> (+)</td>
<td>H</td><td>H</td><td>H</td><td>HCl</td><td> 269-271</td><td> (±)</td>
<td>3-Br</td><td>H</td><td>H</td><td>HCl, 2H<sub>2</sub>O</td><td> 285°</td><td> (±)</td>
<td>3-CO<sub>2</sub>me</td><td>ch<sub>3</sub></td><td>ch<sub>3</sub></td><td>1.5HC1, 3H<sub>2</sub>O</td><td> 235°</td><td> (±)</td>
<td colspan="2">2,5-dichloro H</td><td>H</td><td>HCl, H<sub>2</sub>O</td><td> 251-252</td><td> (±)</td>
<td>3-COOH</td><td>ch<sub>3</sub></td><td>ch<sub>3</sub></td><td>HCl, 1.5H<sub>2</sub>O</td><td> 270</td><td> (±)</td>
<td>2-C1</td><td>Η</td><td>H</td><td>HCl, 1.5H<sub>2</sub>O</td><td> 190-194</td><td> (-)</td>
<td>H</td><td>H</td><td>H</td><td>HCl, 0.5H<sub>2</sub>O</td><td> 266-69</td><td> (-)</td>
The erfmdungsgemäße process for the preparation of compounds of general formula I comprises the outlined in the diagram on the attached figure stages. If desired, it is possible to obtain further chromone derivatives of the general formula I which can be prepared according to the invention, in which R 4 has a meaning other than hydroxyl, by treating compounds of the formula II in FIG. 1 by known methods. The general scheme depicted in Figure 1 is more fully illustrated and described by the reaction sequence depicted in Figure 2, which relates to the preparation of one of the preferred compounds of the invention; It is understood that the scope of the invention is not limited thereby.
The preparation of the compound of the formula VHI with η = 1 is known to the person skilled in the art [SM Mc Clavain and RS Berger, J. Am. Chem. Soc., 77, 2848 (1955); A. Ziering, L. Berger, SD Heineman and J. Lee., J. Org. Chem., 12.894 (1947)]. There are two methods described. In the first one stirs 1,3,5-trimethoxybenzene with n-butyllithium at low temperatures, preferably between -60 and -90 °, in inert solvents such as hydrocarbons, eg. B. Pentane or hexane, or ether solvents, e.g. For example, diethyl ether or tetrahydrofuran, for the preparation of the lithio salt, which gives the tetrahydropyridine on stirring with l-methyl-4-piperidone and subsequent acidification. In the second and most preferred method, 1,3,5-trimethoxybenzene is stirred under acidic conditions with 1-methyl-4-piperidone in solvents such as water, acetic acid, alcoholic solvents or a suitable mixture thereof, with glacial acetic acid being particularly preferred.
With reference to the scheme in Figure 2, the tetrahydropyridine derivative of the depicted formula VM (ie
-11Nr. 389875
Formula VIII where n = 1) is hydroborated using direct addition of BFB etherate to a slurry of sodium borohydride in diethylene glycol dimethyl ether under anhydrous conditions and in an inert atmosphere of direct-forming diborane maintained by passing nitrogen or argon through it. The reaction temperature is kept between 20 and 90 °, but a temperature range of 50-60 ° C is preferred. The resulting Organoborankomplex is first treated with hydrochloric acid and then oxidized by the addition of alkali and hydrogen peroxide. The compound thus obtained is a trans-alcohol of formula IXA and is converted to the cis-alcohol of formula XIA by oxidation and subsequent reduction. The oxidation of the trans-alcohol of the formula IXA is carried out by means of a combination of reagents, namely acid chlorides, wherein oxalkyl chloride is preferred, dimethyl sulfoxide and triethylamine and is known to those skilled in the art as oxidation according to Swem. The ketone of the formula XA formed by oxidation of the compound of the formula IXA is reduced by means of hydride reagents, preferably diborane, lithium borohydride or sodium borohydride. A variety of solvents are compatible with sodium borohydride, but proton-containing solvents such as methanol, ethanol and isopropanol are preferred. By maintaining a higher reaction temperature, the cis-isomer can be obtained stereoselectively.
The cis-isomer can be further obtained by fractional crystallization of its acid addition salts, which are formed with optically active acids such. B. (-) - and / or (+) - dibenzoyltartaric acid.
Optionally, the cis isomer can also be esterified with an optically active acid such as (-) - menthyloxyacetic acid, and the resulting diastereomeric esters can subsequently be separated by conventional methods such as fractional crystallization or chromatography.
The cis-hydroxy compound of the formula XIA is acetylated with acetic anhydride and acidic catalysts such as aluminum chloride, boron trifluoride etherate and tin (TV) chloride, boron trifluoride etherate being particularly preferred as the reagent. When a large excess of boron trifluoride etherate is used, demethylation also takes place at the same time, and only the desired methoxyl group is demethylated in a regiospecifically manner to give a compound of formula ΧΠΑ wherein R is -COCHβ. The hydrolysis of this compound with an alkali metal hydroxide leads to compounds of the formula ΧΠΑ where R = H. The compound of formula ΧΠΑ is then converted into the chromone by methods known per se, two of which are described here. In the first method, the compound of formula XIIA with R = H at room temperature and in inert solvents such as ether, tetrahydrofuran, dioxane or hydrocarbon solvents such as hexane with ethyl acetate and alkali metal or NaH, preferably sodium metal stirred; when the ester is a low-boiling liquid as in the present example, it is also usable as a solvent. The reaction is usually complete after one to ten hours to yield the diketone of formula ΧΙΠΑ where R = H, which is cyclized on stirring with mineral acids such as hydrochloric acid or sulfuric acid to the formula IA chromone. In the second method, a compound of formula ΧΠΑ is esterified with R = Ac with a suitable acid, for. B. Benzoic acid, and the ester obtained with a base such. As alkali metal hydroxide, in an inert solvent such as. B, THF, dioxane or pyridine to form the chromone of the formula IA is formed. This is entmethoxylated with pyridine hydrochloride to obtain the hydroxyveibound of the depicted Formula IB. Using the corresponding esters instead of ethyl acetate, various 2-substituted chromones can be prepared.
The Dimethoxychromon of the formula IA can be entmethoxyliert apart from AICI3, BBr ^ or HBr / acetic acid also by means of other acidic reagents. The Entmethoxylierung carried out by heating the Dimethoxychromonderivate with pyridine hydrochloride for a period of 2 to 10 hours at 180 ° C. In some cases, the addition of high boiling amines to the pyridine hydrochloride may be advantageous.
The synthetic scheme of Figure 2 can be used for the preparation of compounds of formula I with R5 = H, alkyl (different from methyl), cycloalkyl, aralkyl and aryl apply. Compounds of the formula I in which R 1 has the same meaning as above can also be prepared from the corresponding N-methyl compounds, ie R 5 = CH<sub>3</sub> (Compounds of formula IB) by one of the known methods. A typical procedure is apparent from the scheme of Figure 3, where a compound of formula IB is treated with R5 = CH3 after protection of the hydroxyl groups with cyanogen bromide and then acid or alkaline hydrolyzed to compounds with R5 = H (compound of formula XIV). This compound, when treated with suitable electrophilic reagents such as halides, acid chlorides, tosylates or enones, gives compounds having R 5 = alkyl, cycloalkyl, aralkyl or aryl, the compound of the depicted Formula XVII being a specific example. According to Figure 3 is 5,7-dihydroxy-2-methyl-8- [4 '- (rcyclopropylmethyl-3<sup>,</sup>-hydroxy) piperidinyl] -4H-1-benzopyran-4-one of the depicted Formula XVII by peracetylation of 5,7-dihydroxy-2-methyl-8- [4 '- (3'-hydroxy-1-methyl) -piperidinyl] 4H-1-benzopyran-4-one of Formula IB with acetic anhydride and sodium acetate at 80-90 ° C. The peracetylated product of formula XIV is stirred with cyanogen bromide in chloroform to give, in the presence of potassium carbonate, 5,7-diacetyl-2-methyl-8- [4 '- (3'-acetoxy-2-cyano) -piperidinyl] -4H-1-one. benzopyran-4-one of the formula XV, which, after heating with 2N hydrochloric acid at 110 ° C. for 5 hours, hydrolyzed and N-demethylated product 5,7-dihydroxy-2-methyl-8- [4 '- (3'- hydroxy) -12Nr. 389875 piperidinyl] -4H-1-benzopyran-4-one of the formula XVI. On heating with cyclopropylmethyl chloride in isobutyl alcohol, the N-cyclopropylmethyl derivative of the depicted formula XVII is obtained therefrom.
Compounds of the formula I in which R is<sub>2</sub> Dialkylaminomethyl be prepared by reacting the corresponding chromone with R<sub>2</sub> = H with a secondary amine hydrochloride and paraformaldehyde in dioxane or alcoholic solvents heated to reflux compounds of formula I with R<sub>2</sub> = NO<sub>2</sub> are conveniently prepared by stirring the corresponding chromone with R<sub>2</sub> = H made with acetic acid and concentrated nitric acid. Compounds of the formula I with R<sub>2</sub> = NH<sub>2</sub> is obtained from the corresponding nitro derivatives by hydrogenation over 10% Pd / C.
Compounds of formula I wherein one of the Ry groups is bromo is prepared by stirring the corresponding chromones with Rβ = H with N-bromosuccinimide in dimethylformamide.
Another feature of the invention is that the compounds of the invention represented by the formula I have pharmacological properties. In particular, they show an anti-inflammatory and immunomodulating effect on laboratory animals. These properties are evidenced by the results of the subsequent pharmacological tests carried out to evaluate the compounds of the invention and their salts.
Systemic and anti-inflammatory effect on carrageenin-induced paw edema in the rat
Male Charles Foster rats (120-150 g) were fasted for 18 hours with water ad libitum. The test compound dissolved in distilled water was orally administered. The control group received distilled water. 0.05 ml of 0.5% carrageenin suspension was injected subcutaneously into the sole region of the left hind paw. The paw volume was determined from the carrageenin injection using a Maclab differential volume meter and 3 and 6 hours thereafter. The percent paw volume decrease was calculated according to the following equation:
Mean edema - Mean edema volume in the - volume in the
Carrier control test group
-x 100 =% paw volume decrease
Mean volume of edema in the vehicle control
The ED ^ Q value was calculated from the dose / effect curve. Six animals were used per group.
The results with representative compounds according to the invention and their salts are given in Table 4, the substituents referring to the following formula Ia:
<img file="AT389875B_D0010.tif" />
-13Nr. 389875
Table 6
Compounds of the formula Ia
<td colspan="5">connection</td><td rowspan="2">ED<sub>50</sub> mg / kg p. 0th</td>
<td>cis</td><td><sup>R</sup>1</td><td><sup>R</sup>2</td><td><sup>R</sup>5</td><td>X</td>
<td> (-)</td><td>ch<sub>3</sub></td><td>Η</td><td></td><td>hci.h<sub>2</sub>O</td><td> 10,0</td>
<td> (-)</td><td>ch<sub>3</sub></td><td>H</td><td>ch<sub>3</sub></td><td>HCl</td><td> 9,0</td>
<td> (±)</td><td><sup>C</sup>2<sup>H</sup>5</td><td>H</td><td>ch<sub>3</sub></td><td>HCl.1.5 Η<sub>2</sub>Ο</td><td> 10,5</td>
<td> (±)</td><td>11-C3H7</td><td>H</td><td>ch<sub>3</sub></td><td>hci.h<sub>2</sub>O</td><td> 6,8</td>
<td> (-)</td><td>n-CßHy</td><td>H</td><td>Η</td><td>HCl, 5H<sub>2</sub>O</td><td> 5,8</td>
<td> (±)</td><td>phenyl</td><td>H</td><td>Η</td><td>HCl, 2H<sub>2</sub>O</td><td> 5,7</td>
<td> (±)</td><td>2-chlorophenyl</td><td>H</td><td>Η</td><td>HCl, H<sub>2</sub>O</td><td> 2,7</td>
<td> (±)</td><td>4-aminophenyl</td><td>H</td><td>Η</td><td>2HC1,2H<sub>2</sub>O</td><td> 7,4</td>
<td> (±)</td><td>4-chlorophenyl</td><td>H</td><td>Η</td><td>HCl, 1.5H<sub>2</sub>O</td><td> 7,0</td>
<td> (±)</td><td colspan="2">2,4-dichlorophenyl Η</td><td>Η</td><td>HCl, 2.5H<sub>2</sub>O</td><td> 5,7</td>
<td> (±)</td><td>4-fluorophenyl</td><td>H</td><td>Η</td><td>HCl, H<sub>2</sub>O</td><td> 7,4</td>
<td> (±)</td><td>2-fluorophenyl</td><td>H</td><td>Η</td><td>HCl, 2H<sub>2</sub>O</td><td> 7,6</td>
<td></td><td>2-pyridyl</td><td>H</td><td>Η</td><td>HCl, 5H<sub>2</sub>O</td><td> 5,7</td>
<td> (-)</td><td>2-chlorophenyl</td><td>H</td><td>Η</td><td>HCl, 2H<sub>2</sub>O</td><td> 2,4</td>
<td> (-)</td><td>phenyl</td><td>H</td><td>Η</td><td>HCl, 5H<sub>2</sub>O</td><td> 1,3</td>
Reverse passive Arthus reaction (RPA) in the rat Charles Foster rats of both sexes weighing 150-180 g were sorted into groups of six animals each. 24 hours before the RPA was triggered, the rats were shorn from the mid-back area and fasted overnight. The test compound was administered orally one hour before the induction of Arthus reaction. The RPA response was induced by intradermal injection of 0.1 ml of appropriately diluted rabbit anti-BSA serum Immediately following the intradermal injections, the rats received 0.5 ml 0.4% bovine serum albumin intravenously. Four hours after the intradermal exposure, the groups of animals were each killed by breaking a throat. The entire thickness of the skin was removed from the back of each animal and a 12 mm diameter disc was punched out with a metal punch at the site of the antiserum injection. The wet weight of the skin site was determined as soon as possible. The edema caused by the RPA was measured as the difference (expressed in mg) between the wet weight of the antibody-injected site and the normal rabbit serum injected site.
The results are expressed as percent inhibition of the edema by the compound over the edema induced in the untreated control animals.
The results with representative compounds of the invention and their salts are given in Table 7
-14Nr. 389875
Table 7
Effect on the reverse passive Arthus reaction (RPA) in the rat
Compound of formula la
<td></td><td></td><td>connection</td><td></td><td></td><td>DOSE</td><td rowspan="2">% Inhibition</td>
<td>ice cream</td><td><sup>R</sup>1</td><td><sup>r</sup>2</td><td><sup>r</sup>5</td><td>X</td><td>mg / kg</td>
<td> (-)</td><td>ch<sub>3</sub></td><td>Η</td><td>CH<sub>2</sub>-<</td><td>hci.h<sub>2</sub>O</td><td> 1,25 2,5 5,0 10,0 20,0</td><td> 23,0 49,7 74,0</td>
<td> (-)</td><td>ch<sub>3</sub></td><td>Η</td><td>ch<sub>3</sub></td><td>HCl</td><td> 1,25 2,5 5,0 10,0 20,0</td><td> 40,31 39,11 40,13 45,17 64,73</td>
<td> (±)</td><td>c<sub>2</sub>H<sub>5</sub></td><td>Η</td><td>ch<sub>3</sub></td><td>HC1.1 1/2 H<sub>2</sub>O</td><td> 1,25 2,5 5,0 10,0 20,0</td><td> 16,0 34,31 41,65 43,60 77,10</td>
<td> (±)</td><td></td><td>Η</td><td>ch<sub>3</sub></td><td>hci.h<sub>2</sub>O</td><td> 1,25 2,50 5,0 10,0 20,0</td><td> 26,0 32,0 44,0 55,0 65,0</td>
<td> (-)</td><td><sup>n</sup>'<sup>c</sup>3<sup>H</sup>7</td><td>Η</td><td>ch<sub>3</sub></td><td>hci.h<sub>2</sub>O</td><td> 1,25 2,5 5,0 10,0 20,0</td><td> 42.7 41,3 63.7 72,1</td>
<td> (±)</td><td>phenyl</td><td>Η</td><td>ch<sub>3</sub></td><td>HC1.2H<sub>2</sub>O</td><td> 1,25 2,5 5,0 10,0 20,0</td><td> 57.5 55.6 68,1 90.6 95.7</td>
<td> (±)</td><td>o-chlorophenyl</td><td>Η</td><td>ch<sub>3</sub></td><td>hci.h<sub>2</sub>O</td><td> 1,0 2,0 4,0</td><td> 37,0 60,0 80,0</td>
-15Nr. 389875
Table 7 (continued)
<td colspan="5">Verbindune</td><td rowspan="2">Dose mg / kg p. 0th</td><td rowspan="2">% Inhibition</td>
<td>cis</td><td><sup>R</sup>1</td><td>r<sub>2</sub></td><td><sup>R</sup>5</td><td>X</td>
<td> (±)</td><td>2,4-dichloro- phenyl</td><td>H</td><td>ch<sub>3</sub></td><td>HCl 2.5 H<sub>2</sub>O</td><td> 1,25 2,5 5,0 10,0 20,0</td><td> 0 41,7 57,2 49,5 76,1</td>
<td> (±)</td><td>p-fluorophenyl</td><td>H</td><td>ch<sub>3</sub></td><td>hci.h<sub>2</sub>O</td><td> 1,25 2,5 5,0 10,0 20,0</td><td> 24.4 37.4 61.5 90,0 86,2</td>
<td> (±)</td><td>o-fluorophenyl</td><td>H</td><td>ch<sub>3</sub></td><td>HC1.2H<sub>2</sub>O</td><td> 1,25 2,5 5,0</td><td> 0 11,5 52,7</td>
<td> (±)</td><td>2-pyridyl</td><td>H</td><td>ch<sub>3</sub></td><td>HCl.1.5 H<sub>2</sub>O</td><td> 1,25 2,5 5,0 10,0 20,0</td><td> 0 12,0 43,0 90,0 90,0</td>
<td> (-)</td><td>2-chlorophenyl</td><td>H</td><td>ch<sub>3</sub></td><td>HCl.1.5 H<sub>2</sub>O</td><td> 1,25 2,5 5,0 10,0 20,0</td><td> 34,0 48.8 70,0 98.8</td>
<td> (-)</td><td>phenyl</td><td>H</td><td>ch<sub>3</sub></td><td>HC1.1 / 2H<sub>2</sub>O</td><td> 1,25 2,5 5,0 10,0 20,0</td><td> 26,2 64,5 92,2</td>
The invention is illustrated by, but not limited to, the following examples.
Example 1 1-Methyl-4- (2,4,6-trimethoxyphenyl) -1,2,3,6-tetrahydropyridine
N-methylpiperidone (2.8 mol) is added with stirring to a solution of trimethoxybenzene (2.38 mol) in glacial acetic acid (750 ml), keeping the temperature of the reaction mixture below 25 ° C. After completion of the addition, hydrogen chloride is bubbled through the reaction mixture, heated to 95-100 ° C for 3 seconds, then concentrated and the residue is diluted with water. The aqueous solution is extracted with ether, the ether separated and the aqueous layer made alkaline with concentrated sodium hydroxide solution. The precipitate thus obtained is filtered off, washed with water and dried. Recrystallization from petroleum ether (60 ° -80 ° C) gives 550 g of 1-methyl-3 (2,4,6-trimethoxyphenyl) -1,3,3,6-tetrahydropyridine of melting point 118-122 ° C.
Analysis: Calculated for ϋ- ^ Η ^ ΝΟβ.Ο, ίΕ ^ Ο
C, 66.17; H, 8.08; N, 5.14%
Found: C, 67.75; H, 7.56; N, 5.03%
-16Nr. 389875
Example 2 (±) trans-3-hydroxy-4- (2,4,6-trimethoxyphenyl) -1-methylpiperidine
A solution of BFβ etherate (42 ml) in diethylene glycol dimethyl ether (42 ml) is added dropwise to a cooled mixture of 1-methyl-4- (2,4,6-trimethoxyphenyl) -1,3,3,6-tetrahydropyridine (20 g) and sodium borohydride (12 g) in diethylene glycol dimethyl ether (140 ml). The mixture is heated at 50 ° C. for one hour and then the cooled reaction mixture is treated with water (20 ml) and then with concentrated HCl (116 ml). The mixture is stirred for two hours at 50-60 ° C, cooled and made alkaline with sodium hydroxide solution. Hydrogen peroxide solution (30%, 20 ml) is then added and heated to 50-60 ° C with stirring for two hours. The solution is cooled and extracted with ethyl acetate. The ethyl acetate extract is concentrated in vacuo. The residue is acidified with 2N HCl, extracted with ethyl acetate and the organic layer is separated off. The aqueous layer is then made alkaline with caustic soda and extracted with ether. The ether extract is washed with brine, dried over sodium sulfate and concentrated to give a solid residue, which is recrystallised from hot water to give trans-3-hydroxy-4- (2,4,6-trimethoxyphenyl) -1-methylpiperidine ( 12 g). Yield: 12 g; Melting point 88 ° - 89 ° C.
Analysis: Compound as oxalate, calculated for Ο ^^ βΝΟψΟ, 5 (COOH) 2.1.75H2O
C, 56.5; H, 7.5; N, 4.12%
Found: C, 56.37; H, 8:14; N, 4.84%
Example 3 f ±) 1-methyl-4- (2,4,6-trimethoxyphenyl) -piperidin-3-one
To a solution of oxyalkyl chloride (20 mL) in dry methylene chloride (500 mL) cooled to -60 ° C is added dropwise dimethylsulfoxide (35 mL) under nitrogen and stirred for 5-10 minutes. Then a solution of (±) -trans-3-hydroxy-4- (2,4,6-trimethoxyphenyl) -l-methyl-piperidine (62 g) in methylene chloride (300 ml) is added while maintaining the temperature of the Reaction mixture at -60 ° C holds. After the addition, the mixture is stirred for 15 minutes and triethylamine (155 ml) is added. Then the reaction mixture is allowed to warm to a temperature of -30 ° C, diluted with water and made alkaline with sodium carbonate.
The organic layer is separated and the aqueous layer extracted with ethyl acetate. The organic layers are combined, washed with brine, over anhydrous Na<sub>2</sub>SO<sub>4</sub> dried and concentrated to a solid residue, which upon crystallization from isopropanol gives the desired product (47 g) of melting point 110-112 ° C.
Analysis: Compound hydrochloride, calculated for C jgH ^ NC ^ Cl C, 51.2; H, 7:39; N, 3.98; CI, 10.09%
Found; C, 51.77; H, 7,16; N, 3.75; CI, 11.45%
Example 4 (±) cis-3-hydroxy-4- (2,4,6-frimethoxyphenyl) -l-methyl-piperidine
Sodium borohydride (10 g) is added with stirring to a refluxing solution of 1-methyl-4 (2,4,6-trimethoxyphenyl) -piperidin-3-one in absolute ethanol. Then it is stirred for a further hour and heated to reflux. On cooling, the reaction mixture is diluted with water, then concentrated to remove the ethanol and extracted with chloroform. The chloroform extract is washed with water, dried over anhydrous sodium sulphate and concentrated to a solid residue which upon crystallization from acetone gives the desired product (29.2 g) of melting point 124-125 ° C
Analysis: Compound as HCl salt; calculated for C15H24NO4CI C, 56.69; H, 7.55; N, 4.4; CI, 11.18%
Found: C, 56.78; H, 7.72; N, 3.93; CI, 11.91%
Example 5 (±) cis-3-Hvdroxv4- (3<sup>,</sup>-acetvl4'.6<sup>,</sup>-dimethoxv-2'-hvdroxv) -phenvl-l-methvlpiperidin
BFβ etherate (107.6 ml) is added dropwise to a solution of cis-3-hydroxy-4- (2,4,6-trimethoxyphenyl) -lmethylpiperidine (35 g) in methylene chloride (500 ml) under cooling in an ice bath. Thereafter, 76.2 ml of acetic anhydride are added dropwise. The reaction is then stirred for 24 hours at room temperature, diluted with water, made alkaline with sodium carbonate and extracted with methylene chloride. The extract is concentrated and the residue (37 g) is dissolved in methanol (200 ml) and stirred for 2 hours with 5% aqueous potassium hydroxide solution (500 ml). Then concentrated in vacuo and the residue extracted with chloroform. The residue obtained after concentration of the chloroform extract is then purified by chromatography on silica gel to give cis-3-hydroxy-4- (3'-acetyl-4<sup>,</sup>,6<sup>,</sup>-dimethoxy-2'-hydroxy) -phenyl-lmethylpiperidine (28 g) of melting point 215-218 ° C (as the HCl salt).
-17Nr. 389875
Analysis: Compound as HCl salt, calculated for C jgH ^ NOjCl C, 55.57; H, 6.94; N, 4.05; CI, 10.27%
Found: C, 55.24; H, 7.04; N, 3.88; CI, 10.40%
Example 6:
General procedure for the preparation of cis / trans 5,7-dimethoxy-2-fRp-8-r4 '- (3'-hydroxy-1-methyl) piperidinyn-4H-1-benzopyran-4-ones
The solution of cis / trans-3-hydroxy-4- (3'-acetyl-4,6-dimethoxy-2'-hydroxy) phenyl-1-methylpiperidine (1 equiv.) Is treated with a suitable ester (3 equiv.). and Na metal (-10 equiv) or Na hydride (-5 equiv) in dry dioxane or dimethylformamide at room temperature or at 70-80 ° C (see Table 8). Then, water is carefully added and extracted with chloroform. The organic phase is separated, slightly concentrated, saturated with HCl gas and then stirred for one hour. The solution is then removed by adding Na<sub>2</sub>CO<sub>3</sub> made basic and extracted with chloroform. The chloroform extract is washed over anhydrous Na<sub>2</sub>SO<sub>4</sub> dried, concentrated in vacuo and purified by column chromatography (over silica gel). Thereafter, a thin layer chromatography (5% methanol in CHCl3 + 1% by volume NH4OH: Rf value 0.5-0.7) can be carried out.
By the general procedure given, the compounds listed in Table 8 below and in Example 6a were prepared.
Tahfill ^.
Preparation of cis / trans compounds of the formula Ie (R<sub>2</sub> = H, R<sub>4</sub> = OH, Rg and Rp = CH<sub>3</sub>; free base)
<td><sup>R</sup>1</td><td>ester</td><td>solvent</td><td>base</td><td>Temp.</td><td>Mp ° C</td>
<td>Methyl (±)</td><td>ethyl acetate</td><td>ethyl acetate</td><td>N / A</td><td>reflux</td><td> 236-38</td>
<td> (±)</td><td>II</td><td>II</td><td>lt</td><td>tf</td><td> 228-29</td>
<td>O</td><td>II</td><td>lt</td><td> 11</td><td>lt</td><td> 228-30</td>
<td>Ethyl (+)</td><td>ethyl propionate</td><td>ethyl propionate</td><td>II</td><td>70-80 ° C</td><td>240-42 (HCl)</td>
<td>n-propyl (+)</td><td>ethyl butyrate</td><td>dioxane</td><td>lt</td><td>II</td><td> 196-97</td>
<td> (±)</td><td>II</td><td>II</td><td>II</td><td>II</td><td> 202-04</td>
<td> (-)</td><td>II</td><td>II</td><td>II</td><td>II</td><td> 202-04</td>
<td>n-butyl (±)</td><td>Ethylvaleriat</td><td>lt</td><td>II</td><td>II</td><td></td>
<td>Phenyl (+)</td><td>methylbenzoate</td><td>DMF</td><td>Close</td><td>RT</td><td>232-34 (HCl)</td>
<td> (-)</td><td>II</td><td>II</td><td>lt</td><td>II</td><td> 225-27</td>
<td>2-chlorophenyl (±)</td><td>Methyl-2- chlorobenzoate</td><td> «1</td><td>lt</td><td> «</td><td>190-91 (HCl)</td>
<td> (-)</td><td> 11</td><td>lt</td><td>lt</td><td>II</td><td> 110</td>
<td>p-bromophenyl (±)</td><td>Methyl-2- bromobenzoate</td><td>II</td><td>II</td><td>II</td><td> 167-70</td>
<td>p-chlorophenyl (±)</td><td>Methyl-2- chlorobenzoate</td><td>II</td><td>II</td><td>II</td><td></td>
<td colspan="2">2,4-dichlorophenyl (±) methyl-2,4-dichlorobenzoate</td><td>II</td><td>II</td><td>II</td><td>179-81 (HCl)</td>
<td>2-fluorophenyl (±)</td><td>Methyl-2- fluorobenzoate</td><td>II</td><td>II</td><td>II</td><td></td>
<td>4-fluorophenyl (+)</td><td>Methyl 4- fluorobenzoate</td><td>lt</td><td>II</td><td>II</td><td> 212-14</td>
<td>4-methylphenyl (+)</td><td>Methyl 4- methylbenzoate</td><td>II</td><td>n</td><td>II</td><td> 185</td>
<td>2-pyridyl (±)</td><td>methylpicolinate</td><td>II</td><td>II</td><td>lt</td><td> 208-10</td>
<td>4-pyridyl (±)</td><td>Methylisonicotinat</td><td>II</td><td>II</td><td></td><td> 215-17</td>
Example 6a ;.
cis-5.7-dimethoxy-2-methyl-8-r4 '- (3'-hvdroxv-r-methyl) -piperidinyn-4H-l-benzopyran-4-one
A solution of cis-3-hydroxy4- (3'-acetyl-4 ', 6<sup>,</sup>-dimethoxy-2'-hydroxy) -phenyl-1-methylpiperidine (10g) in ethyl acetate (500ml) at reflux, and sodium (7g) is added in small portions. Man stirs and
-18Nr. 389875 heated at reflux for 2 to 3 hours. After cooling, the mixture is diluted with water and the organic layer separated. This is then concentrated to half its volume, treated with concentrated HCl (10 ml) and stirred for about one hour. Then dilute with water, make the aqueous layer with Na<sub>2</sub>CO<sub>3</sub> alkaline and extracted with chloroform. The chloroform extract is washed over anhydrous Na<sub>2</sub>Dried, concentrated in vacuo and purified by column chromatography on silica gel to give the desired product (8 g). Recrystallized from chloroform / petroleum ether, mp 236-238 ° C (HCl salt).
Analysis: Compound as dihydrochloride, calculated for CjgH<sub>2</sub>gNOgCl<sub>2 </sub>C, 50.46; H, 6.66; N, 2.68; CI, 15.87%
BsiSMlJj.
General Demethylation Procedure for Preparing cis / trans-5,7-dihydroxy-2- (Rj) -8- [4 '- (3'-hydroxymethyl) piperidinyl] -4H-1-benzopyran-4-one hydrochloride: dimethoxychromone (1.0 g), pyridine hydrochloride (5-10 g) and quinoline (0.5 ml) are mixed and heated at 180-190 ° C. for 2-3 hours. The reaction mixture is then allowed to cool, water (1 ml) is added and basified by adding solid sodium carbonate. The semi-solid product is extracted thoroughly with 20% methanol in chloroform, the organic phase is concentrated and purified by column chromatography (silica gel, 15% by volume of methanol in chloroform with the addition of 1% by volume of NH<sub>4</sub>OH as an element; Rf: 0.4-0.7). By treatment with ethereal HCl one receives the hydrochloride salt.
The general procedure given is used to prepare the compounds listed in Table 9 below:
Table 9 (Formula Ie with R<sub>2</sub> = Rg = R9 = H, R4 = OH)
<td> *1</td><td>X</td><td>mp ° C</td><td>[Alpha] 2 °<sub>D</sub></td>
<td>methyl</td><td>HCl</td><td> 237 - 240</td><td> (±)</td>
<td>methyl</td><td>HCl</td><td> 243</td><td> + 29,5°</td>
<td>methyl</td><td>HCl</td><td> 241-242</td><td> -27,5°</td>
<td>ethyl</td><td>HCl, 1.5H<sub>2</sub>O</td><td> 230-233</td><td> (±)</td>
<td>n-propyl</td><td>HCl, H<sub>2</sub>O</td><td> 190 -192</td><td> (+)</td>
<td>n-propyl</td><td>HCl, 0.5H<sub>2</sub>O</td><td> 197 - 200</td><td> + 33,01°</td>
<td>n-propyl</td><td>HCl, 0.5H<sub>2</sub>O</td><td> 198 - 201</td><td> - 25,91</td>
<td>phenyl</td><td>HCl, 2H<sub>2</sub>O</td><td> 273 - 275</td><td> (±)</td>
<td>phenyl</td><td>HCl, H<sub>2</sub>O</td><td> 266 - 269</td><td> - 50.4°</td>
<td>2-chlorophenyl</td><td>hci, h<sub>2</sub>O</td><td> 198-200</td><td> (±)</td>
<td>2-chlorophenyl</td><td>HCl, 1.5H<sub>2</sub>O</td><td> 190 -194</td><td> -3,4°</td>
<td>4-bromophenyl</td><td>HCl, 2H<sub>2</sub>O</td><td> 215</td><td> (±)</td>
<td>4-chlorophenyl</td><td>HCl, 1.5H<sub>2</sub>O</td><td> 225</td><td> (±)</td>
<td>2,4-dichlorophenyl</td><td>HCl, 2.5H<sub>2</sub>O</td><td> 165 -166</td><td> (+)</td>
<td>2-fluorophenyl</td><td>HCl, 2H<sub>2</sub>O</td><td> 263 - 265</td><td> (±)</td>
<td>4-fluorophenyl</td><td>HCl, H<sub>2</sub>O</td><td> 285 - 287</td><td> (±)</td>
<td>4-methylphenyl</td><td>HCl, 1.5H<sub>2</sub>O</td><td> 247 - 249</td><td> (±)</td>
<td>2-pyridyl</td><td>HCl, 1.5H<sub>2</sub>O</td><td> 229</td><td> (±)</td>
<td>4-pyridyl</td><td>2HC1,2H<sub>2</sub>O</td><td> 278 - 280</td><td> (±)</td>
Example 8
Cleavage of (+) - cis-3-hydroxy-1-methyl-4- (2,4,6-trimethoxyphenyl) -piperidine
Dissolve the racemic cis-3-hydroxy compound (90 g) in methanol (300 ml), add (-) dibenzoyltartaric acid (126.4 g) in methanol (200 ml) and heat to boiling. Diisopropyl ether (about 500 ml) is added slowly and the clear solution is allowed to cool. The tartrate salt slowly crystallizes out. This is filtered off and recrystallized five times from methanol / diisopropyl ether, [alpha]<sup>2</sup>^ = +
-19Nr. 389875
48.3 ° (MeOH). The tartrate salt (43 g) is suspended in water (200 ml), added with hydrochloric acid (2N, 100 ml) and stirred. The reaction mixture is extracted with ethyl acetate (5 times per 100 ml). The tartaric acid is recovered from the vinegar ester extract. The aqueous layer is made alkaline with sodium carbonate and extracted with chloroform. The chloroform extract is dried over anhydrous sodium sulfate and concentrated to give the (+) - 3-hydroxy compound, 17.7 g, mp 109-1 ° C, [alpha]<sup>20</sup>]) = + 53.81 ° (methanol).
The filtrates from the tartrate crystallizations are combined and the free base recovered as described above. Dissolve the free base (20 g) in methanol (110 ml), add (+) - dibenzoyltartaric acid (29 g) and heat the solution to boiling. Then add slowly diisopropyl ether (110 ml). Upon standing at room temperature, the tartrate crystallizes. It is filtered off and recrystallized three times from methanol / diisopropyl ether mixture. Yield: 20.2 g, [alpha]<sup>20</sup>D = -49 ° (MeOH). The free base is isolated as described above, yield: 8.2 g, m.p. 109-111 ° C, [alpha]<sup>20</sup>] = 54.13 ° (methanol).
Optically pure isomers were prepared from optically pure (±) - or (-) - cis-3-hydroxy-4- (3-acetyl-4,6-dimethoxy-2-hydroxy) -phenyl-1-methylpiperidine as in the following examples 9 and 10 made:
Bisspinsla (-) - cis -3-hydroxy-4-i3'-acetyl-4'6'-dimethoxy-2'-hydroxy) -phenyl-1-methyldiperidine
Treat (-) - cis-3-hydroxy-4- (2 ', 4', 6'-trimethoxyphenyl) -1-methylpiperidine in the same manner as in Example 5, giving (-) - cis-3 Hydroxy-4- (3'-acetyl-4 ', 6'-dimethoxy-2'-hydroxy) -phenyl-1-methylpiperidine of melting point 184-86 ° C, [alpha]<sup>20</sup>D = -32.63 ° (MeOH, c = 0.614)
Example 10 (+) - Cis-3-hydroxy-4 - ('3'-acetyl-4'6'-dimethoxy-2'-hydroxypropyl) -phenyl-1-methylpiperidine
Treat (+) - cis-3-hydroxy-4- (2 ', 4', 6'-trimethoxyphenyl) -1-methylpiperidine in the same manner as in Example 5, giving (+) - cis-3. Hydroxy-4- (3'-acetyl-4 ', 6'-dimethoxy-2'-hydroxy) -phenyl-1-methylpiperidine of melting point 184-85 ° C, [alpha]<sup>20</sup>]) = + 34.47 ° (MeOH, c = 0.586).
Example 11 f -) - cis -5,7-dimethoxy-2-methyl-8-r4<sup>,</sup>-(<sup>,</sup>3'-hydroxy-r-methyD-piperidinyll-4H-l-benzopyran-4-one
Treat (-) - cis-3-hydroxy-4- (3'-acetyl-4 ', 6'-dimethoxy-2<sup>,</sup>-hydroxy) phenyl-1-methylpiperidine in the same manner as in Example 6, giving (-) - cis-5,7-dimethoxy-2-methyl-8- [4 '- (3'-hydroxy-r-methyl ) -piperidinyl] -4H1-benzopyran-4-one of melting point 228-30 ° C, [alpha]<sup>20</sup>]) = -80.59 ° (MeOH, c = 0.59).
Example 12 (+) - cis -5.7-Dimethoxy-2-methyl-8-r4 '- (3'-hydroxy-r-methyl) -piperidinyn-4H-1-benzopyran-4-one
Treat (+) - cis-3-hydroxy-4- (3'-acetyl-4<sup>,</sup>,6<sup>,</sup>-di-methoxy-2<sup>,</sup>-hydroxy) -phenyl-1-methylpiperidine in the same manner as in Example 6, giving (+) - cis-5,6-dimethoxy-2-methyl-8- [4 '- (3'-hydroxy-r-methyl ) -piperidinyl] 4H-1-benzopyran-4-one of melting point 228-29 ° C, [alpha]<sup>20</sup>]) = + 84.1 ° (MeOH, c = 0.618)
Example 13 cis -5,7-dihydroxy-2-ethyl-8-r4 '- (3'-hydroxy-r-methyl) -pipeiridinyn-4H-1-benzopyran-4-one hydrochloride
Cis-3-hydroxy-4- (3'-acetyl-4 ', 6'-dimethoxy-2'-hydroxy) phenyl-1-methylpiperidine is treated as in Example 6 with ethyl propionate instead of ethyl acetate and the product is demethylated as in Example 7 described what cis-5,7-dihydroxy-2-ethyl-8- [4 '- (3'-hydroxy-r-methyl) -piperidinyl] -4H-1-benzopyran-4-one hydrochloride from Schmelzpuntk 230 33 ° delivers
Analysis: calculated for Cj9H25NO5.HCLO.5H2O C, 53.3; H, 6.53; N, 3.66; CI, 9.28%
Found: C, 53.1; H, 6.51; N, 3.83; CI, 9.45%
Example 14 cis -5,7-dihydroxy-2-n-propyl-8-r4<sup>l</sup>-f3'-hydroxy-r-methyl) -piperidinyll-4H-l-benzopyran-4-one hydrochloride
Cis-3-hydroxy-4- (3'-acetyl-4 ', 6'-dimethoxy-2 is treated<sup>,</sup>hydroxy-phenyl) -l-methylpiperidine as in Example 6 with ethyl butyrate instead of ethyl acetate and the product demethoxylates as described in Example 7, giving cis-5,7-dihydroxy-2-n-propyl-8- [4 '- ( 3'-hydroxy-r-methyl) -piperidinyl] -4H-l-benzopyran-4-one hydrochloride of melting point 190-92 ° C provides
-20Nr. 389875
Analysis: Calculated for C<sub>2</sub>q H<sub>2</sub>7N = 5.HC1.H<sub>2</sub>O
C, 55.74; H, 6.70; Ν, 3.61; CI, 9.16%
Found: C, 56.25; H, 6.65; N, 3.52; CI, 9.39%
Example 15 cis - (-) - 5,7-Dihydro-2-methyl-8-r4 '- (3'-hydroxy) -piperidinvn-4H-1-benzopvran4-one
Cis - (-) - 5,7-Dihydroxy-2-methyl-8- [4'-3'-hydroxy-r-methyl) -piperidinyl] -4H-1-benzopyran-4-one (5
g) with acetic anhydride (25 ml) and sodium acetate (4.5 g) at 90 ° C. for 12 hours. The acetic anhydride is distilled off in a high vacuum and the residue is stirred with ethyl acetate. The portion soluble in ethyl acetate is concentrated to dryness. Dissolve the residue in dry chloroform (27 ml), add anhydrous potassium carbonate (5 g) and cool to 0 ° C. Bromocyan (6 g) in dry chloroform (25 ml) is added dropwise. After the addition, the reaction mixture is stirred for 4-5 hours at 40-50 ° C, filtered and the filtrate is washed with a small amount of brine, dried over anhydrous sodium sulfate and concentrated. The residue is heated on the steam bath for 7-8 hours with 1N hydrochloric acid (30 ml). The reaction mixture is made alkaline by addition of solid sodium carbonate and concentrated. The residue is allowed through a
HP-20 column run and elute the product with 20% MeOH in H<sub>2</sub>O. The product is crystallized from MeOH / diisopropyl ether, melting point 300 ° C, [alpha]<sup>2</sup>®<sub>D</sub> = -11.38 ° (MeOH, c = 0.9).
Analysis: Assay as hydrochloride salt, calculated for C jβ HjgNO 3 Cl 2 C, 55.00; H, 5.53; N, 4:27; CI, 10.81%
Found: C, 54.33; H, 5.59; N, 3.93; Ci, 11.21%
Analysis: Calculated for C<sub>2</sub>QH<sub>2</sub>7NOß.HCl.H<sub>2</sub>O
C, 55.74; H, 6.70; N, 3.61; CI, 9.16%
Found: C, 56.25; H, 6.65; N, 3.52; CI, 9.39%
Example 16 cis -fl-5.7-dihydroxy-2-methyl-8-i4'-fl-cyclopropylmethyl-3'-hydroxy '> - piperidinyn-4H-1-benzopyan-4-one hydrochloride
Cis - (-) - 5,7-Dihydroxy-2-methyl-8- [4 '- (3'-hydroxy) -piperidinyl] -4H-1-benzopyran-4-one (1.0 g) is mixed,
Cyclopropyl methyl ketone (1.5 ml), isobutanol (15 ml) and potassium carbonate (3 g) and heated at 90 ° C for 15 hours. The reaction mixture is filtered and the residue is washed with chloroform. The filtrate is concentrated and column chromatographed over silica gel. The compound is eluted with 6% MeOH in chloroform. The addition of ethereal HCl produces the hydrochloride, yield 0.7 g, mp 24951 ° C, [alpha]<sup>20</sup>D = -35.4 ° (MeOH, c = 0.571).
Analysis: Calculated for C jpH ^ NOgCl
C, 57.07; H, 6.51; N, 3.75; CI, 8.87%
Found: C, 57.18; H, 6.51; N, 3.75; CI, 9.44%
-21Nr. 389875
13 sheets
Sheet 1 Sheet 2 Sheet 3 Sheet 4 Sheet 5 Sheet 6 Sheet 7 Sheet 8 Sheet 9 Sheet 10 Sheet 11 Sheet 12 Sheet 13
Every citation, both ways
| Document | Relation | Office | Cited during |
|---|---|---|---|
| EP0137193A2 | Cites | European Patent Office (EPO) | Search report |
31 members in 16 offices
Priority claims4
| Document | Office | Kind | Date |
|---|---|---|---|
| 3612337 | Germany | A | |
| 3612337 | Germany | A | |
| 0260587 | – | – | – |
| DE19863612337 | – | – | – |
Members31
| Document | Office | Kind | |
|---|---|---|---|
| DK185287D0 | Denmark | D0 | |
| PT84654A | Portugal | A | |
| IE870941L | Ireland | L | |
| DK185287A | Denmark | A | |
| EP0241003A2 | European Patent Office (EPO) | A2 | |
| AU7139787A | Australia | A | |
| DE3612337A1 | Germany | A1 | |
| JPS62242680A | Japan | A | |
| IL82149A0 | Israel | A0 | |
| IL82149D0 | Israel | D0 | |
| ZA872555B | South Africa | B | |
| KR870010045A | Republic of Korea | A | |
| EP0241003A3 | European Patent Office (EPO) | A3 | |
| IN164232B | India | B | |
| ATA260587A | Austria | A | |
| PT84654B | Portugal | B | |
| AT389875BThis record | Austria | B | |
| US4900727A | United States of America | A | |
| AU602891B2 | Australia | B2 | |
| EP0241003B1 | European Patent Office (EPO) | B1 | |
| AT95519T | Austria | T | |
| ATE95519T1 | Austria | T1 | |
| DE3787661D1 | Germany | D1 | |
| IL82149A | Israel | A | |
| CA1332238C | Canada | C | |
| JPH0686446B2 | Japan | B2 | |
| ES2060582T3 | Spain | T3 | |
| IE62244B1 | Ireland | B1 | |
| DK169760B1 | Denmark | B1 | |
| KR950009861B1 | Republic of Korea | B1 | |
| HK1006021A1 | Hong Kong, China | A1 |
Numbers
- Publication, DOCDB
- 389875
- Publication, EPODOC
- AT389875B
- Application
- 260587
- Application, DOCDB
- 260587
- Application, EPODOC
- AT260587
Titles2
- English
- PROCESS FOR THE PREPARATION OF 4H-1-BENZOPYRAN-4-ON DERIVATIVES, NEW 4H-1-BENZOPYRAN-4-ON DERIVATIVES AND THEIR USE AS DRUGS
- German
- VERFAHREN ZUR HERSTELLUNG VON 4H-1-BENZOPYRAN-4-ON-DERIVATEN, NEUE 4H-1-BENZOPYRAN-4-ON-DERIVATE UND IHRE VERWENDUNG ALS ARZNEIMITTEL
Classification
- CPC, 6
- C07D405/04
- A61P25/04
- C07D211/42
- A61P37/06
- C07D405/14
- A61P37/08
- IPC, 13
- A61K31 445
- A61K31 44
- A61K31 443
- A61P25 04
- A61P37 06
- A61P37 08
- C07D211 42
- C07D211 70
- C07D211 74
- C07D405 04
- C07D405 12
- C07D405 14
- C07F9 553